NAVITOR™ TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI) SYSTEM
FDA approval adds to Abbott's comprehensive transcatheter structural heart portfolio
Offers minimally invasive alternative to surgery for people with aortic stenosis, a common and life- threatening heart valve disease
FREESTYLE LIBRE®**
NAMED "BEST MEDICAL
TECHNOLOGY" IN THE
LAST 50 YEARS
BY THE GALIEN
FOUNDATION
$14.7B
MEDICAL DEVICES
$7.5B
NUTRITION
$16.6B
DIAGNOSTICS
$4.9B
ESTABLISHED
PHARMACEUTICALS
ETERNA™ SPINAL CORD STIMULATION SYSTEM
FDA approval of the world's smallest implantable, rechargeable spinal cord stimulation system for chronic pain^6
FULL-YEAR 2023 GUIDANCE
$4.30 to $4.505 ADJUSTED DILUTED EPS
Patients can view real-time battery life and charging status updates via the mobile app for iPhone®
*Organic sales growth excludes impact of foreign exchange. For full financial data and reconciliation of non-GAAP measures, please see our press release dated Jan. 25, 2023, available at www.abbottinvestor.com. **Find important safety information about the FreeStyle Libre portfolio: www.freestylelibre.us/safety-information.
^ Smallest size determined by volume in cubic centimeters.
1. On a GAAP basis, full-year 2022 Abbott sales increased 1.3%. 2. Full-year 2022 GAAP diluted EPS was $3.91. 3. Fourth-quarter GAAP diluted EPS was $0.59. 4. Abbott projected full-year 2022 diluted EPS on a GAAP basis of $3.75 to $3.81. 5. Abbott projects full-year 2023 diluted earnings per share from continuing operations under GAAP of $3.05 to $3.25. Abbott forecasts specified items for the full-year 2023 of $1.25 per share primarily related to intangible amortization, restructuring and cost reduction initiatives and other net expenses. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be $4.30 to $4.50 for the full-year 2023. 6. Abbott. Eterna SCS IPG Size Comparison Memo (MAT-2210151); 2022.
FORWARD-LOOKING STATEMENTS
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2021, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Abbott Laboratories published this content on 25 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 January 2023 12:47:03 UTC.
Abbott Laboratories specializes in the research, development, manufacturing and marketing of pharmaceutical and medical products. Net sales break down by family of products as follows:
- diagnostic systems and instruments (39.1%);
- vascular devices (24.7%): endoprosthetic systems, dilation catheters, arterial closures, etc.;
- nutrition products (12.1%): pediatric nutrition products, nutritional supplements, and dietetic products;
- medicine (8.2%): anesthetics, antiviral products, antibiotics, inhibitors, anti-inflammatories, etc.;
- other (15.9%).
Net sales are distributed geographically as follows: the United States (38.5%), Germany (5.8%), China (5.6%), India (4.4%), Switzerland (4.1%), Japan (3.8%), Netherlands (2.7%) and others (35.1%).
ABBOTT LABORATORIES 
